ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1327

Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials

Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Linda Hartman4, Judith Oldenkott5, Björn Svensson6, Ingiäld Hafström7, Siegfried Wassenberg8, Ernest Choy9, John Kirwan10, Robin Christensen11, Maarten Boers12 and Frank Buttgereit13, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 3Charité Universitatsmedizine - Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Charite - University Medicine Berlin, Berlin, Germany, 6Lund University, Lund, Sweden, 7Karolinska Institutet, Stockholm, Sweden, 8Rheumazentrum Ratingen, Ratingen, Germany, 9Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, 10University of Bristol, Bristol, United Kingdom, 11Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 12Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 13Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, clinical trial, corticosteroids, glucocorticoids, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1308–1344) RA – Treatments Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent (“low dose”), administered for rheumatoid arthritis (RA), do as well. Prior studies could not definitively answer this research question: Observational studies are confounded by indication, and individual randomized trials are usually underpowered for small safety signals. The objective was to assess the effects of long-term treatment with low dose GCs in RA on body weight and blood pressure by pooling individual patient data from randomized trials.

Methods: Data from five randomised controlled trials with two-year interventions were pooled.1-5 Intervention groups received GCs at a dose of ≤7.5mg/day prednisone equivalent. Co-primary outcomes were the difference in change from baseline in a) body weight (kg) and b) mean arterial blood pressure (MAP; mmHg). A secondary outcome was difference in the change of number of administered antihypertensive drugs. Several sensitivity and subgroup analyses were conducted. All analyses were based on analyses of covariance, trial ID was included as a random effects factor to account for clustering of patients within trials. Multiple imputation was used to account for missing data under the Intention-To-Treat approach. No imputations were performed for trials with no data collected or available for the given outcome. A detailed prespecified protocol (dx.doi.org/10.17504/protocols.io.x54v9y4d1g3e/v1) with a gatekeeping procedure for statistical testing was followed. All trials originated in Europe (twelve countries), and all allowed concomitant treatment with disease-modifying antirheumatic drugs.

Results: 1,112 participants were included (mean ± SD age 61 ± 15 years; 68% female). A mean DAS28 of 4.87 ± 1.16 indicates moderate disease activity at baseline. Disability was moderate to severe with a median (interquartile range) health assessment questionnaire score of 1.38 (0.80; 2.25). 64% and 67% of patients with available data were ACPA and rheumatoid factor positive, respectively, and the median (interquartile range) disease duration was 1 year (0.42; 7). Most patients (44%) were never smokers. Baseline values for weight and MAP were 73kg ± 14 and 98mmHg ± 12; median number of antihypertensive drugs was 0 (interquartile range 0; 1). After two years, patients on GCs gained mean 1.1kg (95%CI 0.5 to 1.8; p < 0.001; Table) more weight than patients in the control groups. Both groups increased MAP by 2-3mmHg, without difference between the groups (–0.4; 95% CI –3.0 to 2.2 mm Hg; p = 0.19; Table). The change in number of antihypertensive drugs was low and similar in both groups. Results were consistent across sensitivity and subgroup analyses focusing on overweight or hypertensive patients, and when comparing GCs at 5mg/d with 7.5mg/d (data not shown).

Conclusion: We present robust evidence that low dose GCs, taken over two years for the treatment of RA, lead to about one additional kg of weight gain but do not cause changes in blood pressure.

References: 1 Boers et al. Ann Rheum Dis 2022 2 Kirwan et al. NEJM 1995 3 Choy et al. Ann Rheum Dis 2005 4 Wassenberg et al. Arthritis Rheumatol 2005 5 Svensson Arthritis Rheumatol 2005

Supporting image 1

Table. Changes in weight and mean arterial blood pressure in GC and control groups over two years.


Disclosures: A. Palmowski: None; S. Nielsen: None; Z. Boyadzhieva: None; L. Hartman: None; J. Oldenkott: None; B. Svensson: None; I. Hafström: None; S. Wassenberg: AbbVie/Abbott, 6, Eli Lilly, 2, 6, Galapagos, 2, Medac, 6, Merck/MSD, 6, Pfizer, 5, 6, UCB, 2; E. Choy: AbbVie, 2, 6, Amgen, 2, 6, Bio-Cancer, 5, Biogen, 2, 5, Chugai Pharma, 2, 6, Eli Lilly, 2, 6, Fresenius Kabi, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, Janssen, 2, Novartis, 5, Pfizer, 5, 6, R-Pharm, 2, Sanofi, 2, 5, 6, Sanofi-Genzyme, 2, UCB, 2; J. Kirwan: None; R. Christensen: None; M. Boers: Celltrion, 2, 6, Novartis, 2, 6, Pfizer, 2, 6; F. Buttgereit: AbbVie/Abbott, 6, Horizon Therapeutics, 5, Pfizer, 5, 6, Roche, 6.

To cite this abstract in AMA style:

Palmowski A, Nielsen S, Boyadzhieva Z, Hartman L, Oldenkott J, Svensson B, Hafström I, Wassenberg S, Choy E, Kirwan J, Christensen R, Boers M, Buttgereit F. Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/effects-of-long-term-low-dose-glucocorticoid-treatment-for-rheumatoid-arthritis-on-body-weight-and-blood-pressure-a-pooled-analysis-of-individual-patient-data-from-five-randomised-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-long-term-low-dose-glucocorticoid-treatment-for-rheumatoid-arthritis-on-body-weight-and-blood-pressure-a-pooled-analysis-of-individual-patient-data-from-five-randomised-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology